Which regimen is better for stem cell mobilization of lymphoma patients?

Transfusion and Apheresis Science

Volumn 48, Issue 3, 2013, Pages 407-410

  Bozdaǧ, Sinem Civriz ^a   Tekgündüz, Emre ^a   Durgun, Gamze ^a   Sarica, Abdurrahman ^a   Demiriz, Itir Şirinoǧlu ^a   Koçubaba, Şerife ^a   Altuntaş, Fevzi ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GEMCITABINE; METHYLPREDNISOLONE; NAVELBINE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CLINICAL ARTICLE; DRUG CHOICE; FEMALE; HUMAN; LYMPHOMA; MALE; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; METHYLPREDNISOLONE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; PROCARBAZINE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; VINBLASTINE;

EID: 84878883037     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.04.027     Document Type: Article

References (32)

1. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000, 95(12):3702-3709.
2. Allan D.S., Keeney M., Howson-Jan K., Popma J., Weir K., Bhatia M., et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. BMT 2002, 29(12):967-979.
3. Siena S., Schiavo R., Pedrazzoli P., Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood stem cell transplantation for cancer therapy. J Clin Oncol 2000, 18:1360-1377.
4. Shpall E.J., Champlin R., Glaspy J.A. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998, 4(2):84-92.
5. Dazzi C., Cariello A., Rosti G., et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. Leuk Lymphoma 2000, 39(3-4):301-310.
6. To L.B., Shepperd K.M., Haylock D.N., et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990, 18:442-447.
7. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:691-697.
8. Ikeda K., Kozuka T., Harada M. Factors for PBPC collection efficiency and collection predictors. Transfusion Apheresis Sci 2004, 31:245-259.
9. Dreger P., Kloss M., Petersen B., et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995, 86:3970-3978.
10. Tarella C., Di Nicola M., Caracciolo D., et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002, 30:725-732.
11. Milone G., Leotta S., Indelicato F., Mercurio S., Moschetti G., Di Raimondo F., et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 2003, 31:747-754.
12. Gertz M.A., Kumar S.K., Lacy M.Q., Dispenzieri A., Hayman S.R., Buadi F.K., et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. BMT 2009, 43:619-625.
13. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
14. Brice P. Managing relapsed and refractory Hodgkin lymphoma. BJH 2008, 141:3-13.
15. Gisselbrecht C. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. ASH Educ Book 2012, 1:410-416.
16. Gisselbrecht C., Glass B., Mounier N., Gill D., Linch D.C., Trneny M., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JCO 2010, 28:4184-4190.
17. Mendler J., Friedberg J. Salvage therapy in Hodgkin's lymphoma. The Oncologist 2009, 14(4):425-432.
18. Colpo A., Hochberg E., Chen Y. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. The Oncologist 2012, 17:80-90.
19. Mollee P., Pereira D., Nagy T., Song K., Saragosa R., Keating A., et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. BMT 2002, 30(5):273-278.
20. Nückel H., Dürig J., Dührsen U. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol 2003, 82:481-486.
21. Di Renzo N., Brugiatelli M., Montanini A., Vigliotti M.L., Cervetti G., Liberati A.M., et al. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma 2006, 47(3):473-479.
22. Fox C.P., McMillan A.K., Bishton M.J., Haynes A.P., Russell N.H. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. Br J Haematol 2008, 141(2):244-248.
23. Crump M., Baetz T., Couban S., Belch A., Marcellus D., Howson-Jan K., et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004, 101(8):1835-1842.
24. Santoro A., Magagnoli M., Spina M., Pinotti G., Siracusano L., Michieli M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007, 92(1):35-41.
25. Suyani E., Sucak G.T., Aki Ş.Z., Yeǧin Z.A., Özkurt Z.N., Yaǧci M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011, 90(6):685-691.
26. Krishnan A., Bhatia S., Slovak M.L., Arber D.A., Niland J.C., Nademanee A., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95(5):1588-1593.
27. Pavone V., Gaudio F., Guarini A., Perrone T., Zonno A., Curci P., et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29(4):285-290.
28. Lee J.L., Kim S., Kim S.W., Kim E.K., Kim S.B., Kang Y.K., et al. Suh CESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005, 35(5):449-454.
29. Pusic I., Jiang S.Y., Landua S., Uy G.L., Rettig M.P., Cashen A.F., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14(9):1045-1056.
30. Milone G., Leotta S., Indelicato F., Mercurio S., Moschetti G., Di Raimondo F., et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 2003, 31(9):747-754.
31. McQuaker I., Haynes A.P., Stainer C., Byrne J.L., Russell N.H. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD341 cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999, 24:715-722.
32. Todd T., Raj S., Camilleri D., Stafford G., Bulusu R., Follows G., et al. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting - a new standard of care in relapsed or refractory Hodgkin lymphoma?. Ann Hematol 2009, 88(11):1107-1112.